Pulmonary Arterial Hypertension and Post-Capillary Pulmonary Hypertension Related to Left Heart Disease

Pulmonary Arterial Hypertension and Post-Capillary Pulmonary Hypertension Related to Left Heart Disease
Release date: June 21, 2021
Expiration date: June 21, 2022

Activity Overview
Pulmonary hypertension is defined hemodynamically as either pre-capillary or post-capillary in etiology. Idiopathic pulmonary arterial hypertension is an example of pre-capillary pulmonary hypertension. This disease is a progressive condition that affects the precapillary pulmonary vasculature. In contrast, post-capillary pulmonary hypertension may be caused by diseases such as heart failure with preserved ejection fraction (HFpEF). Understanding the differences in the clinical presentation, hemodynamic definitions, and diagnosis of pre-capillary and post-capillary pulmonary hypertension is critical to safely and effectively managing these patients. This program will discuss the assessment and diagnosis as well as management options for patients with pulmonary arterial hypertension and post-capillary pulmonary hypertension related to left heart disease.

Target Audience
This activity is designed to meet the needs of cardiologists.

Learning Objectives
Upon completion of the educational activity, participants should be able to:

  • Discuss the clinical presentation, hemodynamic definitions, and diagnosis of pulmonary arterial hypertension and post-capillary pulmonary hypertension related to left heart disease
  • Review the recommended treatment for pulmonary arterial hypertension
  • Identity a collaborative care management approach for patients with pulmonary arterial hypertension

Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all pre-test questions, completed the post-test and evaluation, and have received a digital copy of your certificate.  You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected]

Pulmonary Arterial Hypertension and Post-Capillary Pulmonary Hypertension Related to Left Heart DiseaseCE credit provided by AKH Inc., Advancing Knowledge in Healthcare.

ACCME Jointly accredited In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Faculty
Barry H. Greenberg, MD, FACC
Distinguished Professor of Medicine
Director, Advanced Heart Failure Treatment Program
UC San Diego
La Jolla, CA

Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

DISCLOSURES

Name

Relationship

Commercial Interest

Barry H. Greenberg, MD, FACC

Consultant/Advisor

Boehringer Ingelheim; Cytokinetics; EBR Systems; Ionis Pharmaceuticals; Merck & Co.; MyoKardia; Vifor Pharma; Viking Therapeutics; Windtree Therapeutics

Margaret Varnell Clark, MS, RN, RRT, NPS (medical writer)

N/A

Nothing to disclose

Dorothy Caputo, MA, BSN, RN, CE Director of Accreditations/Lead Nurse Planner

N/A

Nothing to disclose

AKH Staff and Planners

N/A

Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

 

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.